Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) EBIT (2017 - 2025)

Historic EBIT for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$142.0 million.

  • Arcus Biosciences' EBIT fell 3523.81% to -$142.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$375.0 million, marking a year-over-year decrease of 1792.45%. This contributed to the annual value of -$330.0 million for FY2024, which is 294.12% up from last year.
  • Arcus Biosciences' EBIT amounted to -$142.0 million in Q3 2025, which was down 3523.81% from -$8.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year EBIT high stood at $281.0 million for Q4 2021, and its period low was -$142.0 million during Q3 2025.
  • Moreover, its 5-year median value for EBIT was -$78.1 million (2021), whereas its average is -$61.5 million.
  • Over the last 5 years, Arcus Biosciences' EBIT had its largest YoY gain of 64274.87% in 2021, and its largest YoY loss of 513453.61% in 2021.
  • Arcus Biosciences' EBIT (Quarter) stood at $281.0 million in 2021, then plummeted by 126.33% to -$74.0 million in 2022, then fell by 22.97% to -$91.0 million in 2023, then dropped by 13.19% to -$103.0 million in 2024, then plummeted by 37.86% to -$142.0 million in 2025.
  • Its EBIT stands at -$142.0 million for Q3 2025, versus -$8.0 million for Q2 2025 and -$122.0 million for Q1 2025.